<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

PF 477736 - PF 00477736

產(chǎn)品貨號(hào)

Axon 1379 CAS [952021-60-2] MF C22H25N7O2MW 419.48 Purity: 98% Optical purity: 99% ee Soluble in DMSO Description Chk1 inhibitor with Ki values of 0.49 and 47 nM for Chk1 and Chk2 respectively. A proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity References Certificates Categories Extra info JW Janetka et al, Inhibitors of Checkpoint Kinases: From discovery to the clinic. Curr. Opin. Drug Discov. & Devel. 2007, 10(4), 473-486. ? S. Ashwell and S Zabludoff. DNA Damage Detection and Repair Pathways Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy. Clin. Cancer Res. 2008, 14(13), 4033-4037. Certificate of Analysis Material Safety Data Sheet Cell Cycle Regulation Cell Signaling & Oncology Stem Cell p53-Tumor Suppression DNA-damage Response EC 2.7.11.1 CHK Pfizer Licensed Products CHK1 inhibitor Chemical name (R)-2-Amino-2-cyclohexyl-N-[2-(1-methyl-1H-pyrazol-4-yl)-6-oxo-5,6-dihydro-1H-[1,2]diazepino[4,5,6-cd]indol-8-yl]-acetamide Source information Pfizer compound; Sold for research purposes under agreement from Pfizer Inc. Parent CAS No. [952021-60-2] Order Size Unit Price Stock 2 mg €70.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

PF 477736 - PF 00477736

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 1379

CAS [952021-60-2]

MF C22H25N7O2
MW 419.48

Purity: 98%
Optical purity: 99% ee
Soluble in DMSO

PF 477736

Description

Chk1 inhibitor with Ki values of 0.49 and 47 nM for Chk1 and Chk2 respectively. A proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity

JW Janetka et al, Inhibitors of Checkpoint Kinases: From discovery to the clinic. Curr. Opin. Drug Discov. & Devel. 2007, 10(4), 473-486.

S. Ashwell and S Zabludoff. DNA Damage Detection and Repair Pathways Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy. Clin. Cancer Res. 2008, 14(13), 4033-4037.

Certificate of Analysis
Material Safety Data Sheet

Cell Cycle Regulation Cell Signaling & Oncology Stem Cell p53-Tumor Suppression DNA-damage Response EC 2.7.11.1 CHK Pfizer Licensed Products

CHK1 inhibitor

Chemical name

(R)-2-Amino-2-cyclohexyl-N-[2-(1-methyl-1H-pyrazol-4-yl)-6-oxo-5,6-dihydro-1H-[1,2]diazepino[4,5,6-cd]indol-8-yl]-acetamide

Source information

Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Parent CAS No.

[952021-60-2]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>